Abstract
All clinicians, whether in primary or secondary care settings, are likely to encounter patients on this new anticoagulant. Therefore, it is imperative that clinicians are aware of the risks and benefits associated with dabigatran.
Cite
CITATION STYLE
APA
Syyed, N., Ansell, M., & Sood, V. (2014). Dabigatran (Pradaxa ®): Surgeon’s friend or foe? British Dental Journal, 217(11), 623–626. https://doi.org/10.1038/sj.bdj.2014.1051
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free